UNITED STATES PATENT AND TRADEMARK OFFICE

#### BEFORE THE PATENT TRIAL AND APPEAL BOARD

## TRUTEK CORP. Petitioner

٧.

MATRIXX INITIATIVES, INC. Patent Owner

U.S. Patent No. 10,736,931

Case PGR2021-00005

PETITION FOR POST GRANT REVIEW UNDER 35 U.S.C. §§ 321-329 AND 37 C.F.R. § 42.200



### **TABLE OF CONTENTS**

I.	INTE	RODUCTION	1	
II.	MAN	NDATORY NOTICES	2	
	A.	Real Party In Interest	3	
	B.	Related Matters (37 CFR § 42.8(b)(2))	3	
	C.	Counsel and Service Information (37 CFR §§ 42.8(b)(3) and 42.10(a))	4	
	E.	Payment of Fees	4	
	F.	Time for Filing Petition	4	
III.		DITIONAL REQUIREMENTS FOR POST GRANT (IEW	5	
	A.	Certification of Grounds For Standing	5	
IV.	OVE	OVERVIEW OF CHALLENGE AND RELIEF REQUESTED		
	A.	Claims For Which Post Grant Review Is Requested	5	
	B.	Prior Art References	5	
	C.	Relief Requested	10	
V.	THE '931 PATENT		11	
	A.	Specification	12	
	B.	Claims	12	
	C.	Prosecution History	12	
	D.	Person of Ordinary Skill in the Art	12	
VI.	CLA	IM CONSTRUCTION	13	
	A.	Independent Claim 1	13	
		1. Luffa Operculata (L. operculata)	13	



### Petition for Post Grant Review of U.S. Patent No. 10,736,931

	2.	S. officinale (V. sabadilla)	14
	3.	Galphimia Glauca (G. glauca)	14
	4.	Inactive ingredients	15
B.	Depe	ndent Claim 2	15
C.	Dependent Claim 31		
D.	Dependent Claim 41		
E.	Dependent Claim 516		
F.	Dependent Claim 616		
G.	Depe	ndent Claim 7	16
H.	Depe	ndent Claim 8	16
l.	Depe	ndent Claim 9	17
J.	Depe	ndent Claim 10	17
K	Depe	ndent Claim 11	17
L.	Depe	ndent Claim 12	17
M.	Depe	ndent Claim 13	18
N.	Depe	ndent Claim 14	18
Ο.	Depe	ndent Claim 15	18
P.	Depe	ndent Claim 16	18
Q.	Depe	ndent Claim 17	19
R.	Depe	ndent Claim 18	19
		ENGED CLAIMS ARE NOT ENTITLED TO A PRIORITY IER THAN JANUARY 23, 2014	19
OVE	RVIEW	OF THE PRIOR ART	19
A.	Simil	<u>asan</u> (Exhibit 1006)	19



VI.

VII.

## Petition for Post Grant Review of U.S. Patent No. 10,736,931

	В	ZICAM (Exhibit 1007)	20
	C.	Weiser (Exhibit 1008)	21
	D.	Clarke (Exhibit 1009)	21
	E.	<u>Liu '574</u> (Exhibit 1010)	22
	F.	TeutM (Exhibit 1011)	22
	G.	Dorsch (Exhibit 1012)	23
	H.	Haslwanter '146 (Exhibit 1013)	23
	I.	<u>Clarot '440</u> (Exhibit 1014)	23
	J.	<u>Clarot '066</u> (Exhibit 1015)	24
	K.	<u>Clarot '107</u> (Exhibit 1016)	24
	L.	<u>Clarot '924</u> (Exhibit 1017)	24
	M.	<u>Clarot '343</u> (Exhibit 1018)	25
	N.	<u>Clarot '628</u> (Exhibit 1019)	25
	Ο.	Ariza (Exhibit 1020)	25
	P.	<u>Clymer '676</u> (Exhibit 1021)	25
	Q.	<u>Davis</u> (Exhibit 1022)	26
	R.	Jefferson (Exhibit 1023)	26
	S.	FDA Advisory (Exhibit 1024)	26
	T.	FDA Ziagen (Exhibit 1025)	27
	U.	Eshkol (Exhibit 1026)	27
	V.	Wiki Phenethanol (Exhibit 1027)	27
	W.	Yuen (Exhibit 1028)	28
VIII.	GRO	UNDS FOR PETITION	28



A.	Claim 1 is obvious and unpatentable under 35 U.S.C. § 103 over <u>Similasan</u> in view of Clarot Patent Application Publications ('107 and '628)
B.	Claim 1 is obvious and unpatentable under 35 U.S.C. § 103 over <u>Similasan</u> in view of <u>Weiser</u> , <u>Clarke</u> , <u>TeutM</u> , and <u>Dorsch</u> , and further in view of <u>Liu '574</u> 30
C.	Claim 2 is obvious and unpatentable under 35 U.S.C. § 103 over <u>Similasan</u> in view of <u>Weiser</u> , <u>Clarke</u> , <u>TeutM</u> , and <u>Dorsch</u> , and further in view of <u>Haslwanter '146</u> and Clarot Patent Application Publications ('440, '066, '107, '924, '343, and '628)
D.	Claims 3-5 are obvious and unpatentable under 35 U.S.C. § 103 over <u>Similasan</u> in view of <u>Weiser</u> , <u>Clarke</u> , <u>TeutM</u> , and <u>Dorsch</u> , and further in view of <u>Ariza</u> , <u>Clymer '676</u> , and Clarot Patent Application Publications ('440, '066, '107, '343, and '628)
E.	Claims 6 and 7 are obvious and unpatentable under 35 U.S.C. § 103 over <u>Similasan</u> in view of <u>Weiser</u> , <u>Clarke</u> , <u>TeutM</u> , and <u>Dorsch</u> , and further in view of Clarot Patent Application Publications ('107, '343, and '628)
F.	Claims 8-10 are obvious and unpatentable under 35 U.S.C. § 103 over <u>Similasan</u> in view of <u>Weiser</u> , <u>Clarke</u> , <u>TeutM</u> , and <u>Dorsch</u> , and further in view of <u>Davis</u>
G.	Claims 11-12 are Obvious and unpatentable under 35 U.S.C. § 103 over <u>Similasan</u> in view of <u>Weiser</u> , <u>Clarke</u> , <u>TeutM</u> , and <u>Dorsch</u> , and further in view of Clarot Patent Application Publications ('107, '924, '343, and '628)
H.	Claims 13 and 14 are obvious and unpatentable under 35 U.S.C. § 103 over <u>Similasan</u> in view of <u>Weiser</u> , <u>Clarke</u> , <u>TeutM</u> , and <u>Dorsch</u> , Clarot Patent Application Publications ('107 and '628) and further in view of <u>Jefferson</u> , <u>Yuen</u> . <u>FDA Advisory</u> , and <u>FDA Ziagen</u>
l.	Claim 15 is obvious and unpatentable under 35 U.S.C. § 103 over <u>Similasan</u> in view of <u>Weiser</u> , <u>Clarke</u> , <u>TeutM</u> , and <u>Dorsch</u> , Clarot Patent Application Publications ('107 and '628) and further in view of <u>Eshkol</u> and <u>Wiki Phenethanol</u>



# DOCKET

## Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

### **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

#### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

